Continuous Biofilm Disrupting Materials

连续生物膜破坏材料

基本信息

批准号：
7612392
负责人：
SHANTHA s SARANGAPANI
金额：
$ 12.4万
依托单位：
INNOVATIVE CHEMICAL/ENVIRONMENTAL TECH
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-02-15 至 2010-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7612392
关键词：
2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole Acids Address Adherence Adhesions Adopted Adverse reactions Antibiotics Area Binding Biological Biological Assay Blood Vessels Body Fluids Butadiene Calcium Calcium Binding Catheters Chelating Agents Chlorhexidine Citrates Citric Acid Clinical Color Complex Deposition Development Devices Diffusion Drug Delivery Systems Drug Formulations Drug resistance Economics Edetic Acid Elderly Environment Event Excipients Filler Film Fluorescence Microscopy Foundations Funding Gastrostomy Goals Growth Health Insurance Health care facility Hospitals Hybrids In Vitro Industry Infection Insurance Ions Kinetics Laboratories Ligands Liquid substance Local Anti-Infective Agents Magnesium Marketing Medical Medical Device Methods Microbial Biofilms Molds Morphology Multi-Drug Resistance Nature Nosocomial Infections Organism Patients Permeability Pharmaceutical Preparations Phase Phase I Clinical Trials Plant Resins Plastics Play Polyethylene Glycols Polymer Chemistry Polymers Polysaccharides Polyurethanes Population Powder dose form Preparation Process Property Proteins Provider Publishing Reporting Research Resistance Role Sampling Serum Silicones Silver Solubility Solutions Stents Sulfadiazine Surface Synthetic Rubber System Technology Temperature Therapeutic Tube Universities Washington Water Weight Work aged antimicrobial bacterial resistance base conditioning controlled release cost crosslink experience hydrophilicity inhibitor/antagonist levan melting microbial microbicide nano nanosized novel pathogen polycarbonate pressure prevent public health relevance success trend

项目摘要

DESCRIPTION (provided by applicant): An increasing pressure to resist the hospital-acquired infection rates by insurance providers is expected to play a crucial role in the growth of the infection resistant treatments and materials according to Frost & Sullivan research. Muti-drug resistant bacterial biofilms pose a constant threat to medical devices and recently the health insurance companies are showing a strong trend of non-coverage of hospital related infection episodes. Technologies such as coating of the catheters or devices with antibiotics or antiseptics like as nano silver, silver sulfadiazine and/or chlorhexidine, antibiotics have been commercialized with limited success due to rapid release rates resulting in depletion of the eluting antimicrobials. Most medical devices such as vascular and other catheters and non-vascular stents are made of thermoplastic medical grade polymers such as polyurethanes. Additives such as colors, inert fillers etc are compounded with a resin under melt conditions, pelletized and then used for extrusion. We propose the idea of incorporating on lab scale, a thermally stable, antimicrobial, biofilm inhibiting formula by compounding it into a medical grade polyurethane followed by extrusion. We will develop compositions with an ability to release active material for up to 30days in sustained manner at effective levels. Such materials could be further optimized to show ultra slow release over several months. (6months is the ultimate target) During the Phase I, for the proof of our concept, we will synthesize and develop formulations that function as antimicrobial inhibitors and form unique silver species that are more soluble and stable in biological media. These will be used as additives at various defined levels into to a medical grade polyurethane matrix using a water insoluble nanosize natural carrier, compounded and processed as flat plastic samples for the Phase I study. We hope to demonstrate a highly controlled long term release from such matrices that provide the surface with biofilm resistance against clinical pathogens in a biological medium with sera. We will create materials with precise concentrations of the active materials and screen them for elution profile, bacterial attachment kinetics and biofilm abrogation. PUBLIC HEALTH RELEVANCE Recent analysis from Frost & Sullivan found that the U.S. antimicrobial treatment markets earned revenues of $175.4M in 2005 with estimates to reach $558.7M by 2012. The market expects to grow with the increasing need to address microbial growth in end-application markets like health care facilities.

描述（由申请人提供）：根据 Frost & Sullivan 的研究，保险公司抵抗医院获得性感染率的压力越来越大，预计将在抗感染治疗和材料的增长中发挥至关重要的作用。多重耐药细菌生物膜对医疗设备构成持续威胁，最近健康保险公司显示出不承保医院相关感染事件的强烈趋势。诸如用抗生素或抗菌剂（如纳米银、磺胺嘧啶银和/或氯己定）涂覆导管或装置等技术，由于快速释放速率导致洗脱的抗菌剂耗尽，抗生素已商业化，但取得的成功有限。大多数医疗器械（例如血管和其他导管以及非血管支架）均由热塑性医用级聚合物（例如聚氨酯）制成。着色剂、惰性填料等添加剂在熔融条件下与树脂混合、造粒，然后用于挤出。我们提出了在实验室规模上加入热稳定、抗菌、生物膜抑制配方的想法，将其复合到医用级聚氨酯中，然后进行挤出。我们将开发能够以有效水平持续释放活性物质长达 30 天的组合物。此类材料可以进一步优化，以显示几个月内的超缓慢释放。（6个月是最终目标）在第一阶段，为了证明我们的概念，我们将合成和开发具有抗菌抑制剂功能的制剂，并形成在生物介质中更易溶解和更稳定的独特银物质。这些将作为各种规定水平的添加剂使用水不溶性纳米级天然载体添加到医用级聚氨酯基质中，并作为扁平塑料样品进行复合和加工以用于第一阶段研究。我们希望证明此类基质的高度受控长期释放，为表面提供生物膜，以抵抗含有血清的生物介质中的临床病原体。我们将创建活性材料浓度精确的材料，并筛选它们的洗脱曲线、细菌附着动力学和生物膜消除。公共健康相关性 Frost & Sullivan 最近的分析发现，2005 年美国抗菌治疗市场的收入为 1.754 亿美元，预计到 2012 年将达到 5.587 亿美元。随着最终应用市场中解决微生物生长问题的需求日益增长，该市场预计将增长。比如医疗保健设施。